Recombinant Cynomolgus CD59 protein(Met1-Glu101), His-tagged

• Cat.No.: CD59-392C
• Product Overview: Recombinant Cynomolgus CD59 (G7PQF7) (Met1-Glu101) was expressed in HEK293 with a polyhistidine tag at the C-terminus.

Specification

• Source: HEK293
• Species: Cynomolgus
• Tag: His
• Protein length: Met1-Glu101
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant cynomolgus CD59 comprises 87 amino acids and has a calculated molecular mass of 10.2 KDa. The apparent molecular mass of it is approximately 18 and 14 KDa respectively in SDS-PAGE.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Reviews

05/09/2022

The quality is very high and the reliability is very helpful for our research results.

03/17/2021

There are no doping impurities, the experimental effect is very good, and I will recommend it to other students.

01/13/2021

Easy to operate and cost-effective.

Q&As

How to explain the role of CD59 in hemolytic disease?

In hemolytic diseases, the deficiency or dysfunction of CD59 may lead to excessive lysis of red blood cells because the formation of the complement C5b-9 complex cannot be effectively prevented.

Are there differences in CD59 expression levels in different types of cells?

Yes, the expression level of CD59 can vary in different cell types. In general, it is expressed higher in blood cells and some tumor cells.

What are some of the technical challenges that laboratories may encounter when researching CD59?

When researching CD59, laboratories may encounter technical challenges such as selecting the appropriate assay, ensuring the quality and consistency of samples, and the complexity of interpreting results. In addition, CD59 expression variations in different cell types and experimental conditions need to be considered.

What diseases are associated with aberrant expression of CD59?

Aberrant expression of CD59 has been associated with a variety of diseases, including but not limited to hemolytic diseases, certain types of cancer, and autoimmune diseases.

How can I measure CD59 expression in the laboratory?

CD59 expression can be detected using flow cytometry, immunofluorescence staining, or western blotting.

Is there a current treatment for CD59?

The current treatment for CD59 is still in the research stage, and there is no drug approved for clinical use. However, some studies are exploring the use of gene therapy or antibody therapy to modulate CD59 expression or function.